Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$4.99 -0.2%	$4.32	$1.00 ▼ $5.87	$44.08M	0.71	143,684 shs	9,608 shs
CLNN Clene	$3.89 +1.7%	$3.61	$2.28 ▼ $6.96	$32.13M	0.55	88,975 shs	35,805 shs
ERNA Ernexa Therapeutics	$2.07 +4.5%	$2.59	$1.75 ▼ $34.35	$15.24M	5.3	200,023 shs	12,141 shs
KPTI Karyopharm Therapeutics	$4.06 +5.4%	$4.56	$3.51 ▼ $16.95	$35.04M	0.24	86,021 shs	45,151 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	0.00%	+8.93%	+18.20%	+44.93%	+177.93%
CLNN Clene	0.00%	+6.41%	-10.75%	+26.49%	-11.78%
ERNA Ernexa Therapeutics	0.00%	+1.02%	-19.18%	-26.17%	-93.86%
KPTI Karyopharm Therapeutics	0.00%	-15.38%	-12.10%	-28.70%	-71.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	1.607 of 5 stars	3.3	3.0	0.0	0.6	1.7	0.0
CLNN Clene	2.9734 of 5 stars	3.6	5.0	0.0	0.0	2.5	0.6
ERNA Ernexa Therapeutics	0.2831 of 5 stars	0.0	3.0	0.0	0.6	1.7	0.0
KPTI Karyopharm Therapeutics	3.635 of 5 stars	3.4	0.0	4.6	1.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	140.48% Upside
CLNN Clene	3.17	Buy	$40.00	929.60% Upside
ERNA Ernexa Therapeutics	0.00	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$37.40	822.09% Upside

Current Analyst Ratings Breakdown

Latest ERNA, KPTI, CLNN, and ATHE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
6/30/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
5/8/2025	CLNN Clene	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$84.00 ➝ $33.00
5/8/2025	CLNN Clene	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/23/2025	CLNN Clene	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
CLNN Clene	$340K	94.50	N/A	N/A	($1.06) per share	-3.67
ERNA Ernexa Therapeutics	$580K	26.27	N/A	N/A	$0.50 per share	4.14
KPTI Karyopharm Therapeutics	$145.24M	0.24	N/A	N/A	($22.10) per share	-0.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/4/2025 (Estimated)
CLNN Clene	-$39.40M	-$4.04	N/A	N/A	N/A	-8,306.00%	N/A	-105.11%	8/6/2025 (Estimated)
ERNA Ernexa Therapeutics	-$44.54M	-$8.31	N/A	∞	N/A	-7,652.75%	N/A	-285.71%	8/12/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)

Latest ERNA, KPTI, CLNN, and ATHE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	CLNN Clene	-$0.49	N/A	N/A	N/A	$0.06 million	N/A
8/5/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.72	N/A	N/A	N/A	$37.92 million	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/7/2025	Q1 2025	CLNN Clene	-$1.10	-$0.50	+$0.60	-$0.09	$0.07 million	$0.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
CLNN Clene	N/A	N/A	N/A	N/A	N/A
ERNA Ernexa Therapeutics	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
CLNN Clene	N/A	1.36	1.36
ERNA Ernexa Therapeutics	N/A	0.21	0.21
KPTI Karyopharm Therapeutics	N/A	1.33	1.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
CLNN Clene	23.28%
ERNA Ernexa Therapeutics	70.55%
KPTI Karyopharm Therapeutics	66.44%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
CLNN Clene	35.30%
ERNA Ernexa Therapeutics	4.49%
KPTI Karyopharm Therapeutics	2.75%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
CLNN Clene	100	8.27 million	5.35 million	Optionable
ERNA Ernexa Therapeutics	10	7.36 million	7.03 million	No Data
KPTI Karyopharm Therapeutics	380	8.64 million	8.40 million	Optionable

ERNA, KPTI, CLNN, and ATHE Headlines

Recent News About These Companies

Karyopharm Therapeutics (NASDAQ:KPTI) Cut to "Neutral" at HC Wainwright

July 19 at 2:19 AM | americanbankingnews.com

HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI)

July 16, 2025 | msn.com

HC Wainwright Begins Coverage on Karyopharm Therapeutics (NASDAQ:KPTI)

July 13, 2025 | americanbankingnews.com

Karyopharm stock tumbles after disclosing failed financing talks

July 11, 2025 | investing.com

Karyopharm lays off more workers as hunt for strategic alternatives turns up short

July 11, 2025 | fiercebiotech.comF

Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway

July 11, 2025 | msn.com

Karyopharm to Cut About 20% of Workforce Amid Ongoing Review

July 11, 2025 | marketwatch.com

Karyopharm Therapeutics Inc News (KPTI) - Investing.com

July 2, 2025 | investing.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | prnewswire.com

Karyopharm to Present at the Jefferies Global Healthcare Conference

June 3, 2025 | prnewswire.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | prnewswire.com

Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now

May 26, 2025 | zacks.com

Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?

May 19, 2025 | zacks.com

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 19, 2025 | prnewswire.com

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 14, 2025 | prnewswire.com

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

May 12, 2025 | zacks.com

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 12, 2025 | prnewswire.com

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

May 8, 2025 | prnewswire.com

Why Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 5.15%

May 6, 2025 | aaii.comA

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 AI Infrastructure Stocks With Strong Growth, Not Hype
By Chris Markoch | June 26, 2025
View 3 AI Infrastructure Stocks With Strong Growth, Not Hype
BigBear.ai: Why a 90% Rally Could Be Just the Start
By Jeffrey Neal Johnson | July 10, 2025
View BigBear.ai: Why a 90% Rally Could Be Just the Start
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
D-Wave Goes International With South Korea Partnership
By Nathan Reiff | June 23, 2025
View D-Wave Goes International With South Korea Partnership
CSX Stock Rally: Strong Options Flow, Analyst Price Targets
By Jeffrey Neal Johnson | July 18, 2025
View CSX Stock Rally: Strong Options Flow, Analyst Price Targets

ERNA, KPTI, CLNN, and ATHE Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$4.99 -0.01 (-0.20%)

As of 11:15 AM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Clene NASDAQ:CLNN

$3.88 +0.07 (+1.70%)

As of 11:15 AM Eastern

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Ernexa Therapeutics NASDAQ:ERNA

$2.07 +0.09 (+4.55%)

As of 11:14 AM Eastern

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Karyopharm Therapeutics NASDAQ:KPTI

$4.06 +0.21 (+5.35%)

As of 11:12 AM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time